  $\alpha$-glucosidase and prolylendopeptidase has altered expression and
activity patterns in neurological disease, type 2diabetes respectively and
several cancers. Here we screened a series 1-29 benzophenone semicarbazone
derivatives for in vitro free radical scavenging, alpha-glucosidase and
prolylendopeptidase inhibition activities. Seven derivatives were identified as
potential free radical scavengers, 14 as alpha-glucosidase, and 9 as
prolylendopeptidase inhibitors. Kinetic studies on the most promising
inhibitors were performed. Compounds 23, 27, 25 and 28 were found as inhibitor
of alpha-glucosidase, while compound 26 inhibited both prolylendopeptidase and
alpha-glucosidase. The binding modes and binding free energy of the multi
targeted inhibitor 26 were predicted by molecular docking studies. These
results provide insights on prolylendopeptidase and alpha-glucosidase
inhibition of compound 26 for further development as therapeutic agents for
neoplastic, neurological, and endocrine disorders.
